University of Wollongong

Research Online
Faculty of Social Sciences - Papers

Faculty of Social Sciences

2014

Concerns about partner infidelity are a barrier to
adoption of HIV-prevention strategies among
young South African couples
Lisa Parker
Futures Group

Audrey Pettifor
University of North Carolina

Suzanne Maman
University of North Carolina

Jabu Sibeko
University of The Witwatersrand

Catherine L. Mac Phail
University of Wollongong, cmacphai@uow.edu.au

Publication Details
Parker, L., Pettifor, A., Maman, S., Sibeko, J. & MacPhail, C. (2014). Concerns about partner infidelity are a barrier to adoption of
HIV-prevention strategies among young South African couples. Culture, Health and Sexuality, 16 (7), 792-805.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Concerns about partner infidelity are a barrier to adoption of HIVprevention strategies among young South African couples
Abstract

As part of a larger study to examine the feasibility and acceptability of a couples-based HIV-prevention
intervention, we conducted formative in-depth interviews with 10 couples to explore topics such as challenges
in practising safer sex, HIV-prevention strategies, gender power and violence, and issues of trust and infidelity.
In this study, both men and women perceived infidelity as ubiquitous in their social context and were
therefore unable to discuss HIV risk and prevention without suspicions of infidelity in their own relationship.
This impacted couples' ability openly and effectively to discuss strategies to prevent HIV and thus may have
contributed to the limited uptake of HIV-prevention strategies, such as condom use and HIV testing. The
contentious nature of safe-sex discussions placed both members of the couple at a higher risk for HIV
acquisition within the partnership. This study sheds light on how existing relationship norms in South Africa
influence HIV-prevention communication within couples and suggests that new ways of approaching
conflictual issues such as mistrust and infidelity are vital in order for HIV-prevention programmes to succeed.
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INTRODUCTION
Mental illness imposes an immense global disease burden, particularly in low and middleincome countries where access to mental health services is lacking (Kessler et al., 2009,
Becker and Kleinman, 2013). Major depressive disorder (MDD) is the second leading
contributor to years lived with disability (YLD) globally, and ranks within the top four
causes of YLDs in all regions worldwide (Vos et al., 2012). In sub-Saharan Africa more
than two-thirds of patients with severe mental illness are unable to access mental health care
and this number rises to approximately 80% for patients with moderate or mild mental
illness (Wang et al., 2007). To address these challenges, the integration of mental health
screening approaches in primary care has been suggested as a mode for increasing access to
care in low and middle-income settings (Collins et al., 2013, Tomlinson et al., 2009b).

NIH-PA Author Manuscript

The implementation of routine mental health screening in sub-Saharan African primary
health care (PHC) settings requires validated rapid screening instruments that can be easily
administered by lay healthcare workers in busy clinics (Freeman et al., 2005, Becker and
Kleinman, 2013). To our knowledge, brief depression screening tools have not been
validated for a general PHC context in sub-Saharan Africa. A limited number of validation
studies of depression screening tools have been conducted against diagnostic reference
standards in sub-Saharan African settings, but these studies have varied in their choice of
context, screening tool, and diagnostic measure, making the results difficult to apply to a
PHC context. (Andersen et al., 2011, Akena et al., 2012a, Akena et al., 2012b, Pence et al.,
2012, Chishinga et al., 2011, Monahan et al., 2009, Myer et al., 2008, Nakimuli-Mpungu et
al., 2012b, Spies et al., 2009, Adewuya et al., 2006, Akena et al., 2013). In particular, the
populations included in these studies, such as university students, household survey
participants, pregnant or postnatal women, or HIV-infected patients, are not easily
generalizable to a PHC population.

NIH-PA Author Manuscript

Depression is a common and debilitating comorbidity of HIV in sub-Saharan Africa. The
reported prevalence of depression in HIV-infected African adults in ranges from 8–60%,
several times greater than prevalence estimates in the general population (Ramirez-Avila et
al., 2012, Hughes et al., 2004, Kagee and Martin, 2010, Myer et al., 2008, Olley et al., 2004,
Lawler et al., 2011, Kinyanda et al., 2011, Nakimuli-Mpungu et al., 2011, NakimuliMpungu et al., 2012a, Tomlinson et al., 2009a). The relationship between MDD and HIV is
complex, as depression can be a risk factor for HIV acquisition as well as a consequence of
HIV infection (Smit et al., 2006, Simoni et al., 2011). However, MDD has long been
recognized as a predictor of negative clinical outcomes among people with HIV (Bing et al.,
2001, Simoni et al., 2011, Owe-Larsson et al., 2009, Lopes et al., 2012). Persons with
depression initiate anti-retroviral treatment (ART) at lower CD4 counts than people without
mental illness, and depressed patients are much less likely to adhere to ART than patients
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who are not depressed (Tegger et al., 2008, Gonzalez et al., 2011, Nakimuli-Mpungu et al.,
2012a, Kaharuza et al., 2006).
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Routine mental health screening in PHC settings, where most HIV-infected patients are
diagnosed and seek regular care, might be a valuable approach to identify both HIV-infected
and HIV-uninfected patients who require further mental health assessment. Routine
depression screening is recommended for HIV infected patients in high-resource settings
and can be an effective way to identify patients at risk for negative outcomes (Shacham et
al., 2009, Schumacher et al., 2012, O’Connor et al., 2009). Depressed HIV-infected patients
who receive treatment for mental health illness have improved ART adherence and
increased quality of life (Yun et al., 2005, Elliott et al., 2002). As interventions to increase
access to early ART are scaled up throughout sub-Saharan Africa and universal HIV
counseling and testing (HCT) becomes the norm, integration of mental health services and
HIV programs could be an important component of ensuring optimal care and treatment
utilization for these two highly comorbid conditions (Stein et al., 2005).

NIH-PA Author Manuscript

Here, we have conducted a validation study of an interviewer-administered brief screening
tool for depression, in a high HIV burden, low literacy PHC population in Johannesburg,
South Africa. We sought to validate the PHQ-9 as a depression screening tool compared to
the internationally validated Mini International Neuropsychiatric Interview (MINI) among
patients undergoing routine HCT in a primary care setting. We also sought to provide
additional evidence of the utility of the PHQ-9 among HIV-infected people in sub-Saharan
Africa.

METHODS
Ethical approvals
The Institutional Review Board at the University of North Carolina (No. 12–1730) and the
Human Research Ethics Committee at the University of Witwatersrand (No. M120725)
approved this study.
Study setting and population

NIH-PA Author Manuscript

Witkoppen Health and Welfare Centre (WHWC) is a high-volume primary health care clinic
in northern Johannesburg, South Africa that provides comprehensive services predominantly
to persons living in densely populated peri-urban formal and informal settlements. At
WHWC, every clinic client with an unknown HIV status or with a negative HIV test more
than three months old routinely undergoes opt-out HCT.
The study population comprised a randomly selected subset of patients who were
undergoing routine HCT at WHWC between September 2012 and April 2013. Participants
were eligible for enrollment if they presented at WHWC for any reason, were at least 18
years old, not pregnant by self-report, could communicate in one of 5 common languages
used by interviewers (English, isiZulu, isiXhosa, seSotho, seTswana), and were able to
provide informed consent. Persons found to be experiencing acute suicidal ideation during
the PHQ-9 were excluded and referred for immediate assistance.
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Measures
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PHQ-9—The PHQ-9 is a 9-item depression screening tool that determines the presence and
frequency of the 9 core depressive symptoms identified in the DSM-IV over the previous 2
weeks. This tool has been widely utilized in Western settings and more recently in subSaharan Africa (Pence et al., 2012, Monahan et al., 2009, Adewuya et al., 2006, Akena et
al., 2013). Scores range from 0–27, with a score of 10 or higher typically used to indicate the
presence of a depressive disorder that would benefit from treatment. While the PHQ-9 was
developed to be self-administered, interviewer-administration has yielded similar results
(Pinto-Meza et al., 2005).
MINI—The MINI International Neuropsychiatric Interview (MINI) is a short, structured
diagnostic interview for major psychiatric disorders. The MINI served as the reference
standard in this study (Sheehan et al., 1998). The MINI is a reliable and valid diagnostic tool
that has been used successfully in South African populations (Myer et al., 2008, Olley et al.,
2004). We used the MINI modules for major depressive disorder (MDD), anxiety disorders
(generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress
disorder), suicidality, and bipolar disorder.

NIH-PA Author Manuscript

Study Procedures
Eligible patients were selected randomly for recruitment each day. Patients were recruited
after clinic registration but prior to undergoing HCT. After providing informed consent, the
patient completed the screening interview, including the PHQ-9, with a trained layinterviewer. Questions about substance abuse and knowledge of HIV status (from prior
testing experiences) were also included in the questionnaire. Socio-demographic information
and clinical information was obtained from the patient’s WHWC clinic file. Due to low
literacy in the study population, the questionnaire was administered by the interviewer and
responses were recorded on a paper form. The questionnaire was translated and conducted in
5 common languages (English, isiZulu, isiXhosa, seSotho, seTswana).

NIH-PA Author Manuscript

After the screening interview, participants immediately completed the MINI interview with
a second study team member who was blinded to the results of the PHQ-9. The MINI
interview was conducted by health care professionals trained in use of the instrument. The
MINI was administered in the same language as the screening interview; an interpreter was
used when needed. Translations of the MINI were completed in the same languages used for
the screening tools and these standard translations were used when needed.
Study data were collected and managed using Research Electronic Data Capture (REDCap)
tools hosted at the University of North Carolina, Chapel Hill (Harris et al., 2009).
Analyses
A positive screen for probable depression was defined as a score ≥10 on the PHQ-9 (Pence
et al., 2012, Adewuya et al., 2006, Akena et al., 2013). Test characteristics including
sensitivity, specificity, and categorical likelihood ratios for the PHQ-9 were calculated
relative to a diagnosis of a current major depressive episode (MDE) on the MINI. A range of
cut-off scores (Data presented for cut-off scores of 8, 10, and 12) was considered for the
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PHQ-9. Categorical likelihood ratios were calculated for the standard scores of ≥5 (mild
depression/anxiety), ≥ 10 (moderate depression/anxiety), ≥ 15 (moderately severe
depression/severe anxiety), and ≥20 (severe depression). Post-test probabilities (analogous
to positive predictive values for a dichotomous test) were calculated for a range of
prevalence values of depression using categorical likelihood ratios. Receiver operating
characteristic (ROC) plots were graphed and the area under the curve (AUC) is reported.
Sensitivity analysis was conducted to assess the possible bias in PHQ-9 test performance
produced by misclassification of MDE by the MINI. Varying combinations of sensitivity
and specificity of the MINI reference standard were considered. In conditional independence
scenarios, which did not assume any relationship between a patient’s score on the PHQ-9
and their score on the MINI, MINI sensitivity was varied from 0.75 to 1.00 and specificity
from 0.97 to 1.00. In conditional dependence scenarios, it was theorized that patients who
underreported depressive symptoms on the PHQ-9 might also underreport on the MINI. For
the conditional dependence assessments, a range of reduced sensitivities of the MINI was
considered for the population who screened negative on the PHQ-9. Stata version 12
(College Station, TX) was used for all analyses.

NIH-PA Author Manuscript

RESULTS
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Between September 2012 and April 2013, 397 persons provided informed consent to
participate in this study. Participants had a median age of 35 years (IQR: 28–46 years) and
most were female (60%). About half of the participants were from South Africa (48%) and
more than a third were from Zimbabwe (37%). Nearly 60% were employed and 30%
reported drinking alcohol (Table 1). Of the 397 participants, 257 (64.7%) tested negative for
HIV on the enrollment date or within the previous 2 weeks and 113 (28.5%) tested positive
at enrollment or were not tested because they told the HIV counselor that they knew their
positive status and were enrolled in HIV care at another clinic (n=9). About two-thirds of
patients (65%) rated their general health status as good, very good, or excellent, while the
remainder reported poor or fair health. Compared to patients who were not depressed,
patients with depression reported poor or fair health more often (p<0.0001) and were more
likely to be female (p=0.06) and HIV-infected (p=0.08). Other demographic characteristics
were similar among depressed and not depressed patients. According to the PHQ-9, 44% of
the participants reported no depression (PHQ9= 0–4), 32% reported mild depression
(PHQ9=5–9), 18% reported moderate depression (PHQ9=10–14), 5% reported moderately
severe depression (PHQ9=15–19), and 1% reported very severe depression (PHQ9≥20).
PHQ-9
Of the 397 persons completing the MINI, 47 (11.8%) met the diagnostic criteria for a current
MDE on the MINI. Of the 47 patients, 19 (40.4%) were experiencing a comorbid anxiety
disorder and 3 (0.76%) met criteria for bipolar spectrum disorder. The most common
comorbid anxiety disorders were generalized anxiety disorder (GAD) and post-traumatic
stress disorder (PTSD). Compared to the MINI, the PHQ-9 performed modestly in this
population. Of the 47 persons meeting criteria for MDE, 37 had a positive PHQ-9
depression screen with the standard cut-off score of 10 or higher, yielding a sensitivity of
78.7% (95% CI: 64.3–89.3) (Table 2). Of the 350 participants who did not meet criteria for
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current major depression on the MINI, 292 had a negative depression screen on the PHQ-9,
corresponding to a specificity of 83.4% (95% CI: 79.1–87.2). An alternate PHQ-9 cut-off
score of 8 in the overall sample yielded a higher sensitivity of 87.2% (95% CI: 74.3–95.2)
and a lower specificity of 73.4% (95% CI: 68.5–78.0). A higher alternate cut-off score of 12
yielded a lower sensitivity of 55.3% (95% CI: 40.1–69.8) and a higher specificity of 89.1%
(95% CI: 85.4–92.2).
In ROC analysis, the PHQ-9 had an area under the curve (AUC) of 0.88 (95% CI: 0.83–
0.92), indicating moderately high accuracy (Figure 1). Likelihood ratios for the commonly
used PHQ-9 categories representing mild (5–9), moderate (10–14), moderately severe (15–
19), and severe (20–27) depression were 0.09, 0.50, 3.89, 6.77, and 22.3 respectively (Table
3). Post-test probabilities for these categories were calculated for a range of pre-test
probability (prevalence) values (Figure 2). At the 11.8% prevalence of MDE seen in the
study population (indicated by vertical line, Figure 2), the post-test probability of depression
for a PHQ-9 score between 10–14 is 34.2%, for a score between 15–20 it is 47.5%, and for a
score higher than 20 it is 75%.

NIH-PA Author Manuscript

Among HIV-positive participants, 15.0% (n=17) met the criteria for MDE compared to
8.9% of the HIV-negative participants. The PHQ-9 performed similarly in the HIV-positive
and HIV-negative populations (Table 2). Among the 113 HIV-infected patients, the PHQ-9
yielded a slightly higher sensitivity and a lower specificity compared to the HIV-negative
population, although these estimates are imprecise as there were only 17 cases of MDE in
the HIV-infected group.
Misclassification of true MDE by the MINI was not likely to have produced substantial bias,
as shown by sensitivity analyses. All scenarios where conditional independence was
considered suggested that the true values of sensitivity and specificity of the PHQ-9 were
underestimated by the observed estimates. Corrected estimates for sensitivity of the PHQ-9
ranged from 0.84 to 0.99 and corrected estimates for specificity of the PHQ-9 ranged from
0.84 to 0.86. Conditional dependence, assessed by reducing the sensitivity of the MINI for
patients screening negative on the PHQ-9, only slightly changed the observed results.
Additionally, the performance of the PHQ-9 did not differ according to the language in
which the interview was conducted.

NIH-PA Author Manuscript

DISCUSSION
In this high HIV burden PHC population in Johannesburg, South Africa, the PHQ-9 showed
high accuracy in correctly classifying cases of current MDE (AUC 0.88) relative to the
reference standard MINI. At the standard cut-off score of 10, the PHQ-9 had moderately
high sensitivity and specificity in the study population. The performance of the PHQ-9 was
similar to that from a range of other settings outside of sub-Saharan Africa (Gilbody et al.,
2007, Manea et al., 2012). Compared to other studies within sub-Saharan Africa, the PHQ-9
performed slightly worse than it did among university students in Nigeria (Adewuya et al.,
2006) or HIV-infected persons in Uganda (Akena et al., 2013), but it performed significantly
better in this study than it did among HIV-infected patients in Cameroon (Pence et al.,
2012). To our knowledge, ours is the only diagnostic validation study of the PHQ-9
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conducted among a general PHC population in sub-Saharan Africa, and it underscores both
the importance of a primary care setting in this region as an access point for identifying
depression and as well an accurate tool to do so.
We found an 11.8% prevalence of MINI-defined current MDE in the overall study sample,
higher than previously found among the general population in South Africa. A nationally
representative household survey found that 4.9% of South Africans had suffered from MDE
in the previous 12 months, as measured by the World Health Organization’s (WHO)
Composite International Diagnostic Interview (CIDI) (Tomlinson et al., 2009a). We would
expect our estimate to be higher than the prevalence from a household survey as our sample
includes chronically ill and disenfranchised patients who are more likely to experience
mental illness.

NIH-PA Author Manuscript

The variation between our prevalence estimate and others from the region may also be
explained by other estimates deriving from differing screening instruments, some of which
have not been validated against diagnostic tools. Additionally, some other prevalence
estimates focus particularly on specific population subsets rather than the general
population. For example, among the HIV-infected subset of this population, depression
prevalence was 15%, comparable to other prevalence estimates of MDD among HIVinfected African persons in studies using diagnostic tools (range ~3–35%) (Adewuya et al.,
2006, Lawler et al., 2011, Nakimuli-Mpungu et al., 2012b, Myer et al., 2008, Akena et al.,
2013, Spies et al., 2009). The high prevalence of comorbid anxiety disorders, particularly
GAD and PTSD, among depressed patients in this population reiterates the need to assess
patients presenting with depressive symptoms for comorbid psychiatric diagnoses, which
can lead to increased psychiatric severity and treatment resistance (Kessler et al., 2005,
Gaynes et al., 1999).

NIH-PA Author Manuscript

When evaluating the clinical utility of the PHQ-9 for depression screening and choosing an
ideal cut-off score for this setting, we considered the prevalence of depression in the
population, the benefits and harms of screening, and the resources available for screening
and follow-up. In our study context, a busy PHC clinic in a resource-scarce setting with one
part-time mental health professional, patients screened by lay-workers using the PHQ-9
would then be evaluated by a PHC clinician who could confirm that a clinical depression
exists and decide whether to begin treatment in the PHC setting or refer to a mental health
professional. In this scenario, the categorical likelihood ratios, which capture the magnitude
of depression, are particularly useful in prioritizing patients compared to the standard
dichotomous cut-off score alone. The standard score of 10 groups together all patients with a
score of 10 or higher-so those who have a score of 11 (moderate depression) and those who
have a score of 20 (severe depression) are considered the same, discarding valuable
information about the degree of illness. In contrast, the categorical likelihood ratios allow
the clinician to prioritize patients based on the magnitude of the depression score and the
post-test probability of disease for a particular value of the PHQ-9. By multiplying the
categorical likelihood ratio for a particular score by the pre-test odds of disease, a post-test
odds can be calculated and easily converted to a post-test probability (Sonis, 1999). A
patient with a PHQ-9 score of 11 at WHWC has a post-test probability of approximately
34% of being depressed as compared to a post-test probability of approximately 75% for a
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patient with a PHQ-9 score of 20. Using the categorical likelihood ratios would allow these
two patients with different likelihoods of depression to be prioritized accordingly for the
limited mental health resources available at WHWC. The categorical likelihood ratios also
allow decision-makers to adjust the pre-test probability value for different groups of patients
by taking into account factors such as medical history (e.g. HIV infection status) or
laboratory data, rather than only the overall prevalence of depression in the general clinic
population. In this more sophisticated approach, one standard cutoff score is not applicable
to all patients in a clinic, but rather the cutoff score differs depending on a number of
important variables specific to each patient.
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In choosing an ideal cut-off score for the PHQ-9, we also considered the relative cost of a
false negative versus a false positive result. In our study setting, where many patients were
coping with chronic diseases such as HIV, it might be reasonable to consider a false
negative, or missing a true case of depression, to be worse than a false positive. Patients with
chronic conditions and comorbid depression are at risk for a multitude of negative outcomes
including poor adherence to treatment and increased morbidity and mortality (Katon, 2011).
Therefore, identifying the maximum number of true depression cases might be considered a
priority, especially among HIV infected patients in whom treatment initiation and adherence
is a significant concern. This approach would come at the expense of a higher number of
false positive screens, creating a higher burden on the clinic to spend time and resources
evaluating patients who are not true depression cases. These choices are ultimately
dependent on the setting in which the tool is applied and the resources available for followup.

NIH-PA Author Manuscript

The strengths and limitations of this study should be considered. The cultural construct of
depression or anxiety in our study setting is likely to be very different from the Western
settings in which the PHQ-9 was first developed. The version of the PHQ-9 used in this
study was the same as that used in Cameroon among HIV-infected patients, which had been
adapted slightly through focus group feedback in Cameroon (Pence et al., 2012). While we
were able to translate the PHQ-9 into local languages, we were unable to conduct additional
focus groups or qualitative interviews in our study setting that would have allowed us to
further adapt the PHQ-9 for culturally-relevant use in this context and ensure that the tool
was well understood by the study population. Although our results did not differ according
to the language in which the PHQ-9 was administered, such qualitative research might have
increased the diagnostic properties of the PHQ-9 in our study. We would encourage other
researchers to conduct preliminary qualitative work when adapting and optimizing screening
tools for use outside of the context in which the tool was originally developed and validated.
While the MINI was used as the reference standard in our study, it is imperfect, especially in
light of the cultural considerations discussed above. However, the MINI has been validated
against other diagnostic interviews, including the CIDI and the Structured Clinical Interview
for DSM Disorders (SCID) and has itself been used as a reference standard for the validation
of many other psychiatric scales (Sheehan et al., 1998). Misclassification or reference-test
bias with use of the MINI is likely to occur to some degree, and will depend partly on the
experience level of the interviewer. Given the rigorous DSM-IV criteria utilized in the
MINI, we believe that false positives will be rare, although false negatives or missing cases
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of true MDE is possible. This would have biased our measured estimates of PHQ-9
sensitivity and specificity downwards. Our sensitivity analyses were consistent with
observed estimates of sensitivity and specificity of the PHQ-9 being underestimated. Given
our observed data, a MINI specificity of anything less than 1 would suggest that the reported
sensitivity of the PHQ-9 is an underestimate of the true sensitivity. Our data were
inconsistent with a MINI specificity less than 0.97 because of the low number of MDE cases
among patients screening negative on the PHQ-9. An additional source of bias could have
arisen through interviewer-administration of the PHQ-9 as participants may be less likely to
report mental health symptoms to an interviewer due to fear of stigmatization. This could
lead to conditional dependence through lower sensitivity of the MINI among patients who
screen negative on the PHQ-9, but sensitivity analysis showed that this would only slightly
affect our observed estimates of PHQ-9 performance.
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Mental health screening in this study was conducted among patients prior to undergoing
HCT. The advantage to this approach is that it allowed us to evaluate the performance of
screening instruments among patients who were HIV-negative as well as the 28.5% of the
study population who tested HIV positive after their participation in this study. Because
patients received their HIV test results after depression screening, new knowledge of an HIV
diagnosis would not have influenced HIV infected patients to screen positive for depression
due to an acute adjustment disorder with a depression reaction. We recognize that the HIVinfected patients in this population are different from those engaging in ongoing HIV care
who have been coping with long-term knowledge of HIV status, and that the prevalence of
mental illness may differ at various time points in HIV care. Other research on depression
and HIV in sub-Saharan Africa has focused mostly on patients who are aware of their HIV
status rather than those who are testing for HIV. Our results contribute important
information to the field as the mental health of HIV-infected patients prior to HCT has not
been evaluated. Identifying patients with underlying depression as early as HCT could help
identify patients at risk of defaulting treatment or care early on. Ideally, we would screen
patients for mental health illness at several time points in HIV care, if resources for followup exist.
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The PHQ-9 performed reasonably well as a screening tool in this high HIV-burden South
African clinic population and was easily implemented by lay health workers. Our results
provide insight on how we can screen for and prioritize often overlooked and highly
prevalent depressive symptoms in low-resource PHC settings in sub-Saharan Africa. Such
an intervention might be especially useful for monitoring high-risk subsets of the population
such as HIV-infected people at risk for defaulting treatment, although further research will
be required to determine how screening for depression can contribute to improved clinical
outcomes. This study provides a framework for implementing depression screening
programs in resource-scarce sub-Saharan African contexts and establishes the PHQ-9 as a
useful screening instrument in these settings.
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Figure 1.

Receiver operating characteristic (ROC) curve for PHQ-9

NIH-PA Author Manuscript
J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 2.

Post-test probability for varying PHQ-9 categories, based on categorical likelihood ratios.
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Characteristics of the study population by depression (N=397)
Characteristic

Total study population*

Depression n (%) or median (IQR)

(n=397)

Yes (n=47)

No (n=350)

<=25

59 (14.9)

4 (8.5)

55 (15.7)

26–35

147 (37.0)

20 (42.6)

127 (36.3)

36–45

87 (21.9)

10 (21.3)

77 (22.0)

46–55

71 (17.9)

10 (21.3)

61 (17.4)

>55

33 (8.3)

3 (6.4)

30 (8.6)

Male

159 (40.1)

13 (27.7)

146 (41.7)

Female

236 (59.5)

34 (72.3)

202 (57.7)

Employed

230 (63.7)

29 (65.9)

201 (63.4)

Unemployed

131 (36.3)

15 (34.1)

116 (36.6)

South Africa

190 (49.9)

27 (57.4)

163 (48.8)

Other country

191 (50.1)

20 (42.6)

171 (51.2)

Any

118 (30.0)

13 (28.3)

105 (30.2)

None

276 (70.1)

33 (71.7)

243 (69.8)

Excellent

60 (15.2)

6 (13.0)

54 (15.5)

Very good

57 (14.5)

4 (8.7)

53 (15.2)

Good

139 (35.3)

10 (21.7)

129 (37.1)

Fair

79 (20.1)

13 (28.3)

66 (19.0)

Poor

59 (15.0)

13 (28.3)

46 (13.2)

Positive

113 (28.5)

17 (36.2)

96 (27.4)

Negative

257 (64.7)

23 (48.9)

234 (66.9)

27 (6.8)

7 (14.9)

20 (5.7)

Age (years)

Gender

Employment status

NIH-PA Author Manuscript

Country of birth

Alcohol use

Perceived health status

HIV status

NIH-PA Author Manuscript

Unknown†
*

Categories may not sum to the total because of missing data

†

Twenty seven participants are of unknown HIV status because they were either: 1) found to be either suicidal or mentally distressed during this
study so HCT was deferred (n=5, 1.3%); 2) they refused to test for HIV after undergoing pre-test counseling (n=6, 1.5%); or 3) the patient skipped
HCT (n= 16, 4%).

J Affect Disord. Author manuscript; available in PMC 2015 October 01.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

37

26

≥10

≥12

38

58

93

312

292

257

TN

21

10

6

FN

55.3 (40.1–69.8)

78.7 (64.3–89.3)

87.2 (74.3–95.2)

Sensitivity (95% CI)

89.1 (85.4–92.2)

83.4 (79.1–87.2)

73.4 (68.5–78.0)

Specificity (95% CI)

15

14

11

≥8

≥10

≥12

15

28

39

FP

81

68

57

TN

6

3

2

FN

64.7 (38.3–85.8)

82.4 (56.6–96.2)

88.2 (63.6–98.5)

Sensitivity (95% CI)

84.4 (75.5–91.0)

70.8 (60.7–79.7)

59.4 (48.9–69.3)

Specificity (95% CI)

TP

20

17

12

Cut-off

≥8

≥10

≥12

22

28

48

FP

212

206

186

TN

11

6

3

FN

52.2 (30.6–73.2)

73.9 (51.6–89.8)

87.0 (66.4–97.2)

Sensitivity (95% CI)

90.6 (86.1–94.0)

88.0 (83.2–91.9)

79.5 (73.7–84.5)

Specificity (95% CI)

PHQ-9 test characteristics at various cut-off scores among HIV-negative patients only (n=257)

TP

Cut-off

TP= True positive, FP= False positive, TN= True negative, FN= False negative

*

41

≥8

FP

PHQ-9 test characteristics at various cut-off scores among HIV-positive patients only (n=113)

TP*

Cut-off

PHQ-9 test characteristics at various cut-off scores among whole study population (n=397)
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Likelihood ratios for commonly used PHQ-9 decision thresholds
Symptom severity

PHQ-9 category

Likelihood ratio

No depression

≤5

0.09

Mild depression

5–9

0.50

Moderate depression

10–14

3.89

Moderately severe depression

15–19

6.77

Severe depression

20–27

22.3
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